Drug Trial Radar · NCT03748186
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Feb 1, 2019
Primary completion
Jun 4, 2024
Study completion Jun 4, 2024
Sponsor
- Lead sponsor
- Sutro Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Conditions
- Ovarian Cancer
- Ovarian Carcinoma
- Ovary Cancer
- Endometrial Cancer
- Endometrioid Adenocarcinoma
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
STRO-002Drug
intravenous antibody drug conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)Time frame: 18 months
- Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002Time frame: 18 months
- Part 1: Define the maximum tolerated dose (MTD) of STRO-002Time frame: 18 months
- Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)Time frame: 24 months
- Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)Time frame: 24 months
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Oncology - Tucson
Tucson, Arizona
UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Sutter Health- Palo Alto Medical Foundation
San Francisco, California
Rocky Mountain Cancer Center
Aurora, Colorado
Yale School of Medicine
New Haven, Connecticut
Miami Cancer Institue, Baptist Health South Florida
Miami, Florida
University of South Florida
Tampa, Florida
Augusta Oncology
Augusta, Georgia
University of Chicago
Chicago, Illinois
Maryland Oncology Hematology
Rockville, Maryland
Minnesota Oncology Hematology
Minneapolis, Minnesota
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
NYU Langone Medical Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Ohio State University, James Cancer Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Prisma Health
Greenville, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Virginia Cancer Specialists
Fairfax, Virginia
Cancer Care Northwest-South Spokane
Spokane, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
Clínica Universidad de Navarra -Madrid
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario HM Sanchinarro - CIOCC
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.